US Phase I Study of ECT-001-CB in Patients With Sickle-Cell Disease

NCT04594031 | Withdrawn Phase 1 DMC FDA Drug

• 1 other identifier: ECT-001.CB.005
• Study Type: interventional
• Target: N/A
• Locations: 1 country
• Sites: 2

Brief Summary

The application of experimental hematopoietic cell transplantation (HCT) therapy in sickle-cell disease (SCD) must strike a balance between the underlying disease severity and the possibility of a direct benefit of the treatment, particularly in pediatric populations. Clinical studies in adults with SCD have focused on interventions that prolong survival and improve the quality of life. Unlike children, adults with SCD are much more likely to have a debilitating complication. As a result, the risk/benefit ratio of HCT is very favorable in adults, particularly if an approach to HCT that defines an acceptable level of toxicity can be established. Whereas hematopoietic stem cell transplantation (HSCT) remains the only curative treatment currently available for patients with SCD, the morbidity, the frequent irreversible damage in target organs and the mortality reported in the natural course of patients with severe SCD are strong incentives to perform HSCTs in younger age groups. For those who lack a matched related donor, CB transplant is an appealing option, but despite been less problematic, CB accessibility related to cell dose of appropriately matched cord blood unit (CBU) remains a significant issue. Through a 7-day culture process of a CBU's hematopoietic stem cell HSCs with the UM171 compound, the total cell dose is increased mitigating this limitation. UM171-CB expansion (ECT-001-CB) allows a greater CB accessibility, the selection of better matched cords that might translate into favourable clinical outcomes as reported in previous trials, including a lower risk of graft-versus-host disease. After CB selection and ex-vivo expansion, ECT-001-CB transplant will follow a myeloablative reduced-toxicity conditioning regimen consisting of rATG, busulfan and fludarabine with doses of all agents optimized to the individual using model-based dosing and will be followed by standard supportive care and GVHD prophylaxis consisting of tacrolimus and MMF.

Conditions

Sickle Cell Disease; Umbilical Cord Blood; Hematopoietic Cell Proliferation

Outcome Measures

Primary Outcomes (7)

• Evaluate feasibility of finding a suitable ECT-001-CB graft for transplantation in the context of SCD.

  Calculate the proportion of recruited SCD patients for whom a suitable CBU (i.e., ≥ 6/8 human leukocyte antigen (HLA) with an appropriate cell dose) is identified.

  Up to 24-months

• Evaluate feasibility of a successfully performing ECT-001-CB transplantation in the context of SCD.

  Calculate the percentage of selected grafts that will be successfully expanded and transplanted with absence of technical hurdles

  During accrual (up to 24-months)

• Evaluate the Safety of ECT-001-CB by evaluating tri-lineage hematopoietic reconstitution

  Measure the time required to achieve neutrophil and platelet engraftment

  Up to 12-Months

• Evaluate the Safety of ECT-001-CB by calculating incidence of acute and chronic GvHD

  Calculate incidence of Acute GVHD and Chronic GVHD as per NIH criteria

  Up to 12-Months

• Evaluate the Safety of ECT-001-CB by evaluating adverse events

  Calculate the Incidence of Adverse Events from the beginning of the conditioning regimen up to 12 months after ECT-001-CB transplant

  Up to 12-Months

• Evaluate the Safety of ECT-001-CB by evaluating incidence of transplant related mortality (TRM)

  Calculate incidence of any mortality related to the investigational product until the end of evaluation period.

  Up to 12-Months

• Evaluate the Safety of ECT-001-CB by incidence of graft failure

  Calculate the incidence of primary and late graft failure

  Up to 100 days

Secondary Outcomes (3)

• Determine the pharmacologic effect of ECT-001-CB by evaluating donor chimerism

  Up to 12-Months post treatment

• Determine the pharmacologic effect of ECT-001-CB by measuring sickle hemoglobin (HbS) in peripheral blood.

  Up to 12-Months post treatment

• Evaluate impact of ECT-001-CB on SCD-related events during the study period.

  Up to 12-Months post treatment

Study Arms (1)

ECT-001-CB

EXPERIMENTAL

* An Umbilical Cord Blood for transplant will undergo CD34+ selection and expansion. The CD34- fraction is infused on Day +1 post-transplant. * Patients will receive standard supportive care and GVHD prophylaxis

Biological: ECT-001-CB (UM171-Expanded Cord Blood Transplant)

Interventions

ECT-001-CB (UM171-Expanded Cord Blood Transplant) BIOLOGICAL

Single ECT-001-CB transplant (CD34+: 2 to 5.75x10E5/kg, CD3+ \>1x10E6/kg)

ECT-001-CB

Eligibility Criteria

• Age: 5 Years - 30 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64)

You may qualify if:

• Be ≥ 5-30 years of age.
• Have a diagnosis of SCD, with either βS/βS, βS/β0, βS/β+ or βS/βC genotype and followed at a center of excellence for SCD with at least 2 years of detailed past medical records available.
• Have severe disease i.e. have experienced one or more of the following SCD related events, in spite of appropriate supportive care measures (e.g. pain management, penicillin prophylaxis):
• Recurrent severe vaso-occlusive crisis (VOC) (≥2 episodes/year in the prior 2 years): an episode of pain lasting \>2 hours severe enough to require care at a medical facility. Note that priapism that lasts \>2 hours and requires care at a medical facility is also considered a VOC. To meet this criterion, subjects must have either experienced hydroxyurea failure at any point in the past (defined as \>1 VOC or ≥1 acute chest syndrome (ACS) after taking hydroxyurea for ≥3 months) or must have intolerance to hydroxyurea (defined as inability to be maintained on an adequate dose of hydroxyurea due to marrow suppression or severe drug-induced toxicity \[e.g. gastrointestinal distress, fatigue\]).
• ACS (≥2 total episodes in the prior 2 years, with at least one episode in the past year), defined as an acute event with pneumonia-like symptoms, hypoxemia and the presence of a new pulmonary infiltrate. To meet this criterion, subjects must have either experienced hydroxyurea failure or have intolerance to hydroxyurea, as defined above.
• History of an overt stroke, defined as a sudden onset neurologic deficit lasting more than 24 hours that is accompanied by cerebral MRI changes.
• patients on chronic transfusions are eligible, provided medical records documenting any of the above severity criteria are available prior to starting the transfusion program.
• Availability of 1 CB unit ≥ 6/8 HLA match (when A, B, C and DRB1 are performed at the allelic level resolution) with of at least CD34+ cell count 1.5 x 105/kg and total nucleated cells (TNC) 1.5 x 107/kg (pre-freeze)
• Have adequate organ function to undergo a myeloablative (reduced toxicity conditioning) HSCT.
• Have a Lansky/Karnofsky performance status of ≥ 80.
• An appropriate and willing HLA-matched sibling donor is not available.

You may not qualify if:

• Prior HSCT or gene-therapy.
• Positive for presence of HIV-1 or HIV-2, hepatitis B virus (HBV), or hepatitis C virus (HCV). (Note that patients who have been vaccinated against hepatitis B \[hepatitis B surface antibody (HBsAb)-positive\] or patients with positive hepatitis B core and/or hepatitis B-e antibodies are also eligible provided viral load is negative by quantitative polymerase chain reaction (qPCR). Patients who are positive for anti-hepatitis C antibody are eligible as long as they have a negative HCV viral load by qPCR). Positive serology for human T-lymphotropic virus-1 (HTLV-1), syphilis (rapid plasma reagin (RPR)), toxoplasmosis.
• Clinically significant and active bacterial, viral, fungal, or parasitic infection as determined by PI.
• A white blood cell count \<2 × 10e9/L, and/or platelet count \<50 × 10e9/L.
• Any prior or current malignancy or myeloproliferative or a significant coagulation or immunodeficiency disorder.
• Advanced liver disease, defined as:
• Persistent aspartate transaminase, alanine transaminase, or direct bilirubin value \>5 times the upper limit of normal (ULN); or
• Cirrhosis or bridging fibrosis; or
• Baseline prothrombin time or partial thromboplastin time \> 1.5 x ULN; or
• in chronically transfused patients a liver iron concentration (LIC) of ≥ 15 mg/g on T2\* Magnetic Resonance Imaging \[MRI\] of liver.
• Left ventricular ejection fraction (LVEF) \<45% and for patients on chronic transfusions a cardiac T2\* \< 10 ms by MRI.
• Baseline estimated glomerular filtration rate \< 60 mL/min/1.73 m2.
• Baseline oxygen saturation \< 85% without supplemental oxygen (excluding periods of SCD crisis or infection).
• Diffusion capacity of carbon monoxide (DLCO) \<50% of predicted (corrected for hemoglobin and/or alveolar volume).
• Any contraindication to general anaesthesia.

Sponsors & Collaborators

• ExCellThera inc.: lead
• California Institute for Regenerative Medicine (CIRM): collaborator

Study Sites (2)

Stanford University School of Medicine

Palo Alto, California, 94304, United States

Location

University of California San Francisco

San Francisco, California, 94158, United States

Location

MeSH Terms

Conditions

Anemia, Sickle Cell

Condition Hierarchy (Ancestors)

Anemia, Hemolytic, Congenital; Anemia, Hemolytic; Anemia; Hematologic Diseases; Hemic and Lymphatic Diseases; Hemoglobinopathies; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities

Study Officials

• Medical Monitor

  ExCellThera inc.

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 28, 2020
• First Posted: October 20, 2020
• Study Start: July 13, 2021
• Primary Completion: September 1, 2023
• Study Completion: February 2, 2024
• Last Updated: July 5, 2022

Record last verified: 2022-06

Data Sharing

• IPD Sharing: Will not share

Locations

US (2)